InvestorsHub Logo
Followers 26
Posts 8986
Boards Moderated 0
Alias Born 12/11/2013

Re: Lemoncat post# 365295

Wednesday, 07/14/2021 12:38:15 PM

Wednesday, July 14, 2021 12:38:15 PM

Post# of 403092
They did have a small trial using tablet release with newer technology...

http://www.ipharminc.com/press-release/2020/2/13/innovation-pharmaceuticals-phase-1-trial-of-brilacidin-for-ulcerative-colitis-meets-primary-endpoints-positive-topline-results-of-oral-brilacidin

Study results show that Brilacidin delayed-release tablets were well tolerated across all treatment cohorts with no serious adverse events reported. Of the 9 subjects treated, 2 subjects on Brilacidin and 2 subjects on placebo experienced at least one adverse event. The adverse events were of mild intensity and none were deemed to be related to study treatment.
Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent IPIX News